ImmunoGenesis Doses First Patient in Phase 1a/1b Clinical Trial of IMGS-001 in Relapsed or Refractory Advanced Solid Tumors
IMGS-001 is the first dual-specific PD-L1/PD-L2 antibody with cytotoxic function designed to treat immune-excluded cancers that are resistant to existing immunotherapies
SIRPant Immunotherapeutics to Present Trial in Progress Poster at the Society for Immunotherapy of Cancer 38th Annual Meeting
Venatorx Pharmaceuticals to Present at IDWeek 2023
– New data to be presented from Phase 3 CERTAIN-1 study with Cefepime-Taniborbactam
– MD Anderson Cancer Center analysis of Cefepime-Taniborbactam in vitro activity against clinically significant gram-negative bacteria isolated from patients with cancer
Strados Labs Announces Pediatric Asthma Study to Validate its Wearable Device in Children with Wheeze
Strados Labs’ RESP™ Biosensor is currently being used in a clinical trial at Lurie Children’s to determine if the technology can accurately detect wheezing and other symptoms of asthma exacerbation in children.
Relmada Therapeutics Announces Efficacy and Safety Results from the Phase 3 LongTerm Study of REL-1017 in Major Depressive Disorder
Patients newly treated with REL-1017 for up to one year experienced rapid, clinically meaningful, and sustained improvements in depressive symptoms and associated functional impairment
Long-term dosing with REL-1017 was well-tolerated, with low rates of adverse events and discontinuations due to adverse events, and no new safety signals were detected
KayoThera, Inc. Nominates First-in-Class, Oral Inhibitor of the Retinoid Pathway in Genetically Defined Oncology Indications as a Development Candidate
Unique safety profile positions KAYO-1609 as the first retinoid pathway inhibitor to enter Investigational New Drug (IND)-enabling studies
Company expects to file IND application with the U.S. Food & Drug Administration (FDA) by the end of 2024
Relmada Therapeutics Announces Dosing of First Patient in Relight, a Phase 3 Trial of REL-1017 for the Adjunctive Treatment of Major Depressive Disorder
Venatorx Pharmaceuticals Announces FDA Acceptance and Priority Review of New Drug Application for Cefepime-Taniborbactam to Treat Complicated Urinary Tract Infections (cUTI), including Pyelonephritis, in Adults
Cefepime-taniborbactam has also demonstrated in vitro activity against CDC Urgent and Serious Threat Pathogens carbapenem-resistant Enterobacterales, multidrug-resistant Pseudomonas aeruginosa and Extended Spectrum Beta-lactamase-producing Enterobacterales
In the CERTAIN-1 cUTI Phase 3 study, cefepime-taniborbactam demonstrated clinical efficacy in patients with infections due to Extended Spectrum Beta-lactamase producing Enterobacterales and carbapenem-resistant Enterobacterales
PDUFA action date set for February 22, 2024
Venatorx Pharmaceuticals Highlights Two Recent Publications Indicating Rising Metallo-Beta-Lactamases for Carbapenem-Resistant Enterobacterales in US
Growing Global Incidence of Carbapenem-Resistant Enterobacterales Metallo-beta-lactamases were the most frequently identified carbapenem resistance
mechanism among Enterobacterales isolates in IHMA global surveillance